<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31858749</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1757-4684</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Feb</Month><Day>07</Day></PubDate></JournalIssue><Title>EMBO molecular medicine</Title><ISOAbbreviation>EMBO Mol Med</ISOAbbreviation></Journal><ArticleTitle>Active poly-GA vaccination prevents microglia activation and motor deficits in a C9orf72 mouse model.</ArticleTitle><Pagination><StartPage>e10919</StartPage><MedlinePgn>e10919</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e10919</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.15252/emmm.201910919</ELocationID><Abstract><AbstractText>The C9orf72 repeat expansion is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD). Non-canonical translation of the expanded repeat results in abundant poly-GA inclusion pathology throughout the CNS. (GA)<sub>149</sub> -CFP expression in mice triggers motor deficits and neuroinflammation. Since poly-GA is transmitted between cells, we investigated the therapeutic potential of anti-GA antibodies by vaccinating (GA)<sub>149</sub> -CFP mice. To overcome poor immunogenicity, we compared the antibody response of multivalent ovalbumin-(GA)<sub>10</sub> conjugates and pre-aggregated carrier-free (GA)<sub>15</sub> . Only ovalbumin-(GA)<sub>10</sub> immunization induced a strong anti-GA response. The resulting antisera detected poly-GA aggregates in cell culture and patient tissue. Ovalbumin-(GA)<sub>10</sub> immunization largely rescued the motor function in (GA)<sub>149</sub> -CFP transgenic mice and reduced poly-GA inclusions. Transcriptome analysis showed less neuroinflammation in ovalbumin-(GA)<sub>10</sub> -immunized poly-GA mice, which was corroborated by semiquantitative and morphological analysis of microglia/macrophages. Moreover, cytoplasmic TDP-43 mislocalization and levels of the neurofilament light chain in the CSF were reduced, suggesting neuroaxonal damage is reduced. Our data suggest that immunotherapy may be a viable primary prevention strategy for ALS/FTD in C9orf72 mutation carriers.</AbstractText><CopyrightInformation>&#xa9; 2019 The Authors. Published under the terms of the CC BY 4.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Qihui</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0001-5733-9820</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mareljic</LastName><ForeName>Nikola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michaelsen</LastName><ForeName>Meike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parhizkar</LastName><ForeName>Samira</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heindl</LastName><ForeName>Steffanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nuscher</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farny</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Czuppa</LastName><ForeName>Mareike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schludi</LastName><ForeName>Carina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graf</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory for Functional Genome Analysis, Gene Center, Ludwig Maximilian University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krebs</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory for Functional Genome Analysis, Gene Center, Ludwig Maximilian University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blum</LastName><ForeName>Helmut</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratory for Functional Genome Analysis, Gene Center, Ludwig Maximilian University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feederle</LastName><ForeName>Regina</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3981-367X</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Monoclonal Antibody Core Facility and Research Group, Institute for Diabetes and Obesity, Helmholtz Zentrum M&#xfc;nchen, German Research Center for Environmental Health (GmbH), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roth</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4869-1627</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arzberger</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuropathology and Prion Research, Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liesz</LastName><ForeName>Arthur</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9069-2594</Identifier><AffiliationInfo><Affiliation>Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edbauer</LastName><ForeName>Dieter</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-7186-4653</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GEO</DataBankName><AccessionNumberList><AccessionNumber>GSE138413</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>617198</GrantID><Agency>EC | Seventh Framework Programme (FP7)</Agency><Country>International</Country></Grant><Grant><Agency>NOMIS Stiftung (NOMIS Foundation)</Agency><Country>International</Country></Grant><Grant><GrantID>EXC 2145</GrantID><Agency>Deutsche Forschungsgemeinschaft (DFG)</Agency><Country>International</Country></Grant><Grant><GrantID>EXC 1010</GrantID><Agency>Deutsche Forschungsgemeinschaft (DFG)</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO Mol Med</MedlineTA><NlmUniqueID>101487380</NlmUniqueID><ISSNLinking>1757-4676</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="Y">Microglia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">
C9orf72
</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">immunotherapy</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword></KeywordList><CoiStatement>Q.Z., N.M., and D.E. are inventors on a patent application filed for poly&#x2010;GA vaccination targeting <i>C9orf72</i> ALS/FTD. C.H. is the chief consultant of ISAR Bioscience.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31858749</ArticleId><ArticleId IdType="pmc">PMC7005532</ArticleId><ArticleId IdType="doi">10.15252/emmm.201910919</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Afgan E, Baker D, Batut B, van den Beek M, Bouvier D, Cech M, Chilton J, Clements D, Coraor N, Gruning BA et&#xa0;al (2018) The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. Nucleic Acids Res 46: W537&#x2010;W544</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6030816</ArticleId><ArticleId IdType="pubmed">29790989</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert M, Mairet&#x2010;Coello G, Danis C, Lieger S, Caillierez R, Carrier S, Skrobala E, Landrieu I, Michel A, Schmitt M et&#xa0;al (2019) Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody. Brain 142: 1736&#x2013;1750</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536853</ArticleId><ArticleId IdType="pubmed">31038156</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, Dejesus&#x2010;Hernandez M, van Blitterswijk MM, Jansen&#x2010;West K, Paul JW III, Rademakers R et&#xa0;al (2013) Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77: 639&#x2013;646</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27: 9115&#x2013;9129</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672191</ArticleId><ArticleId IdType="pubmed">17715348</ArticleId></ArticleIdList></Reference><Reference><Citation>Atanasio A, Decman V, White D, Ramos M, Ikiz B, Lee HC, Siao CJ, Brydges S, LaRosa E, Bai Y et&#xa0;al (2016) C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice. Sci Rep 6: 23204</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793236</ArticleId><ArticleId IdType="pubmed">26979938</ArticleId></ArticleIdList></Reference><Reference><Citation>Axelsen TV, Holm A, Christiansen G, Birkelund S (2011) Identification of the shortest Abeta&#x2010;peptide generating highly specific antibodies against the C&#x2010;terminal end of amyloid&#x2010;beta42. Vaccine 29: 3260&#x2013;3269</Citation><ArticleIdList><ArticleId IdType="pubmed">21371581</ArticleId></ArticleIdList></Reference><Reference><Citation>Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H (2010) Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 224: 472&#x2013;485</Citation><ArticleIdList><ArticleId IdType="pubmed">20546729</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang YJ, Jeng US, Chiang YL, Hwang IS, Chen YR (2016) The glycine&#x2010;alanine dipeptide repeat from C9orf72 hexanucleotide expansions forms toxic amyloids possessing cell&#x2010;to&#x2010;cell transmission properties. J Biol Chem 291: 4903&#x2013;4911</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4777828</ArticleId><ArticleId IdType="pubmed">26769963</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC, Norris DA, Bennett CF, Bishop KM (2016) Results from a phase 1 study of nusinersen (ISIS&#x2010;SMN(Rx)) in children with spinal muscular atrophy. Neurology 86: 890&#x2013;897</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4782111</ArticleId><ArticleId IdType="pubmed">26865511</ArticleId></ArticleIdList></Reference><Reference><Citation>Congdon EE, Sigurdsson EM (2018) Tau&#x2010;targeting therapies for Alzheimer disease. Nat Rev Neurol 14: 399&#x2013;415</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463489</ArticleId><ArticleId IdType="pubmed">29895964</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus&#x2010;Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J et&#xa0;al (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p&#x2010;linked FTD and ALS. Neuron 72: 245&#x2013;256</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus&#x2010;Hernandez M, Finch NA, Wang X, Gendron TF, Bieniek KF, Heckman MG, Vasilevich A, Murray ME, Rousseau L, Weesner R et&#xa0;al (2017) In&#x2010;depth clinico&#x2010;pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. Acta Neuropathol 134: 255&#x2013;269</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5508036</ArticleId><ArticleId IdType="pubmed">28508101</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR (2013) STAR: ultrafast universal RNA&#x2010;seq aligner. Bioinformatics 29: 15&#x2013;21</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Edbauer D, Haass C (2016) An amyloid&#x2010;like cascade hypothesis for C9orf72 ALS/FTD. Curr Opin Neurobiol 36: 99&#x2013;106</Citation><ArticleIdList><ArticleId IdType="pubmed">26555807</ArticleId></ArticleIdList></Reference><Reference><Citation>El&#x2010;Agnaf O, Overk C, Rockenstein E, Mante M, Florio J, Adame A, Vaikath N, Majbour N, Lee SJ, Kim C et&#xa0;al (2017) Differential effects of immunotherapy with antibodies targeting alpha&#x2010;synuclein oligomers and fibrils in a transgenic model of synucleinopathy. Neurobiol Dis 104: 85&#x2013;96</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5954414</ArticleId><ArticleId IdType="pubmed">28476636</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Oeckl P, Steinacker P, Verde F, Barro C, Van Damme P, Gray E, Grosskreutz J, Jardel C, Kuhle J et&#xa0;al (2018) Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology 90: e22&#x2013;e30</Citation><ArticleIdList><ArticleId IdType="pubmed">29212830</ArticleId></ArticleIdList></Reference><Reference><Citation>Frick P, Sellier C, Mackenzie IRA, Cheng CY, Tahraoui&#x2010;Bories J, Martinat C, Pasterkamp RJ, Prudlo J, Edbauer D, Oulad&#x2010;Abdelghani M et&#xa0;al (2018) Novel antibodies reveal presynaptic localization of C9orf72 protein and reduced protein levels in C9orf72 mutation carriers. Acta Neuropathol Commun 6: 72</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091050</ArticleId><ArticleId IdType="pubmed">30075745</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Valera E, Spencer B, Rockenstein E, Mante M, Adame A, Patrick C, Ubhi K, Nuber S, Sacayon P et&#xa0;al (2014) Reducing C&#x2010;terminal&#x2010;truncated alpha&#x2010;synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease&#x2010;like models. J Neurosci 34: 9441&#x2013;9454</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4087215</ArticleId><ArticleId IdType="pubmed">25009275</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang YJ, Prudencio M, Carlomagno Y, Daughrity LM, Jansen&#x2010;West K, Perkerson EA et&#xa0;al (2017) Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72&#x2010;associated amyotrophic lateral sclerosis. Sci Transl Med 9: eaai7866</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5576451</ArticleId><ArticleId IdType="pubmed">28356511</ArticleId></ArticleIdList></Reference><Reference><Citation>Heindl S, Gesierich B, Benakis C, Llovera G, Duering M, Liesz A (2018) Automated morphological analysis of microglia after stroke. Front Cell Neurosci 12: 106</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5917008</ArticleId><ArticleId IdType="pubmed">29725290</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadhav S, Avila J, Sch&#xf6;ll M, Kovacs GG, K&#xf6;vari E, Skrabana R, Evans LD, Kontsekova E, Malawska B, de Silva R et&#xa0;al (2019) A walk through tau therapeutic strategies. Acta Neuropathol Commun 7: 22</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6376692</ArticleId><ArticleId IdType="pubmed">30767766</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, Zhu Q, Gendron TF, Saberi S, McAlonis&#x2010;Downes M, Seelman A, Stauffer JE, Jafar&#x2010;Nejad P, Drenner K, Schulte D et&#xa0;al (2016) Gain of toxicity from ALS/FTD&#x2010;linked repeat expansions in C9ORF72 Is alleviated by antisense oligonucleotides targeting GGGGCC&#x2010;containing RNAs. Neuron 90: 535&#x2013;550</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F et&#xa0;al (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14: 577&#x2013;589</Citation><ArticleIdList><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Khosravi B, Hartmann H, May S, Mohl C, Ederle H, Michaelsen M, Schludi MH, Dormann D, Edbauer D (2017) Cytoplasmic poly&#x2010;GA aggregates impair nuclear import of TDP&#x2010;43 in C9orf72 ALS/FTLD. Hum Mol Genet 26: 790&#x2013;800</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5409121</ArticleId><ArticleId IdType="pubmed">28040728</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontsekova E, Zilka N, Kovacech B, Novak P, Novak M (2014) First&#x2010;in&#x2010;man tau vaccine targeting structural determinants essential for pathological tau&#x2010;tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res Ther 6: 44</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4255368</ArticleId><ArticleId IdType="pubmed">25478017</ArticleId></ArticleIdList></Reference><Reference><Citation>Kverneland AH, Enevold C, Donia M, Bastholt L, Svane IM, Nielsen CH (2018) Development of anti&#x2010;drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology 7: e1424674</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5927482</ArticleId><ArticleId IdType="pubmed">29721387</ArticleId></ArticleIdList></Reference><Reference><Citation>Landen JW, Cohen S, Billing CB Jr, Cronenberger C, Styren S, Burstein AH, Sattler C, Lee JH, Jack CR Jr, Kantarci K et&#xa0;al (2017) Multiple&#x2010;dose ponezumab for mild&#x2010;to&#x2010;moderate Alzheimer's disease: safety and efficacy. Alzheimers Dement (N Y) 3: 339&#x2013;347</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5651443</ArticleId><ArticleId IdType="pubmed">29067341</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M, Bard F, Johnson&#x2010;Wood K, Lee C, Hu K, Griffith SG, Black RS, Schenk D, Seubert P (2005) Abeta42 immunization in Alzheimer's disease generates Abeta N&#x2010;terminal antibodies. Ann Neurol 58: 430&#x2013;435</Citation><ArticleIdList><ArticleId IdType="pubmed">16130106</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YB, Baskaran P, Gomez&#x2010;Deza J, Chen HJ, Nishimura AL, Smith BN, Troakes C, Adachi Y, Stepto A, Petrucelli L et&#xa0;al (2017) C9orf72 poly GA RAN&#x2010;translated protein plays a key role in amyotrophic lateral sclerosis via aggregation and toxicity. Hum Mol Genet 26: 4765&#x2013;4777</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886201</ArticleId><ArticleId IdType="pubmed">28973350</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmer C, Oeckl P, Weishaupt JH, Volk AE, Diehl&#x2010;Schmid J, Schroeter ML, Lauer M, Kornhuber J, Levin J, Fassbender K et&#xa0;al (2017) Poly&#x2010;GP in cerebrospinal fluid links C9orf72&#x2010;associated dipeptide repeat expression to the asymptomatic phase of ALS/FTD. EMBO Mol Med 9: 859&#x2013;868</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494528</ArticleId><ArticleId IdType="pubmed">28408402</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Pattamatta A, Zu T, Reid T, Bardhi O, Borchelt DR, Yachnis AT, Ranum LP (2016) C9orf72 BAC mouse model with motor deficits and neurodegenerative features of ALS/FTD. Neuron 90: 521&#x2013;534</Citation><ArticleIdList><ArticleId IdType="pubmed">27112499</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA&#x2010;seq data with DESeq2. Genome Biol 15: 550</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Arzberger T, Kremmer E, Troost D, Lorenzl S, Mori K, Weng SM, Haass C, Kretzschmar HA, Edbauer D et&#xa0;al (2013) Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico&#x2010;pathological correlations. Acta Neuropathol 126: 859&#x2013;879</Citation><ArticleIdList><ArticleId IdType="pubmed">24096617</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Frick P, Grasser FA, Gendron TF, Petrucelli L, Cashman NR, Edbauer D, Kremmer E, Prudlo J, Troost D et&#xa0;al (2015) Quantitative analysis and clinico&#x2010;pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers. Acta Neuropathol 130: 845&#x2013;861</Citation><ArticleIdList><ArticleId IdType="pubmed">26374446</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallery DL, McEwan WA, Bidgood SR, Towers GJ, Johnson CM, James LC (2010) Antibodies mediate intracellular immunity through tripartite motif&#x2010;containing 21 (TRIM21). Proc Natl Acad Sci USA 107: 19985&#x2013;19990</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2993423</ArticleId><ArticleId IdType="pubmed">21045130</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T et&#xa0;al (2005) Effects of alpha&#x2010;synuclein immunization in a mouse model of Parkinson's disease. Neuron 46: 857&#x2013;868</Citation><ArticleIdList><ArticleId IdType="pubmed">15953415</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT et&#xa0;al (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha&#x2010;synuclein transgenic model of Lewy body disease. PLoS ONE 6: e19338</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084838</ArticleId><ArticleId IdType="pubmed">21559417</ArticleId></ArticleIdList></Reference><Reference><Citation>May S, Hornburg D, Schludi MH, Arzberger T, Rentzsch K, Schwenk BM, Grasser FA, Mori K, Kremmer E, Banzhaf&#x2010;Strathmann J et&#xa0;al (2014) C9orf72 FTLD/ALS&#x2010;associated Gly&#x2010;Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. Acta Neuropathol 128: 485&#x2013;503</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159571</ArticleId><ArticleId IdType="pubmed">25120191</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazor Y, Almog R, Kopylov U, Ben Hur D, Blatt A, Dahan A, Waterman M, Ben&#x2010;Horin S, Chowers Y (2014) Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. Aliment Pharmacol Ther 40: 620&#x2013;628</Citation><ArticleIdList><ArticleId IdType="pubmed">25039584</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwan WA, Falcon B, Vaysburd M, Clift D, Oblak AL, Ghetti B, Goedert M, James LC (2017) Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation. Proc Natl Acad Sci USA 114: 574&#x2013;579</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5255578</ArticleId><ArticleId IdType="pubmed">28049840</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeter LH, Dopper EG, Jiskoot LC, Sanchez&#x2010;Valle R, Graff C, Benussi L, Ghidoni R, Pijnenburg YA, Borroni B, Galimberti D et&#xa0;al (2016) Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol 3: 623&#x2013;636</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4999594</ArticleId><ArticleId IdType="pubmed">27606344</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, Schmid B, Kretzschmar HA, Cruts M, Van Broeckhoven C et&#xa0;al (2013) The C9orf72 GGGGCC repeat is translated into aggregating dipeptide&#x2010;repeat proteins in FTLD/ALS. Science 339: 1335&#x2013;1338</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, Masuda&#x2010;Suzukake M, Hosokawa M, Shimozawa A, Hirai S, Okado H, Hasegawa M (2018) C9ORF72 dipeptide repeat poly&#x2010;GA inclusions promote: intracellular aggregation of phosphorylated TDP&#x2010;43. Hum Mol Genet 27: 2658&#x2013;2670</Citation><ArticleIdList><ArticleId IdType="pubmed">29750243</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak P, Schmidt R, Kontsekova E, Zilka N, Kovacech B, Skrabana R, Vince&#x2010;Kazmerova Z, Katina S, Fialova L, Prcina M et&#xa0;al (2017) Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double&#x2010;blind, placebo&#x2010;controlled, phase 1 trial. Lancet Neurol 16: 123&#x2013;134</Citation><ArticleIdList><ArticleId IdType="pubmed">27955995</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak P, Kontsekova E, Zilka N, Novak M (2018a) Ten years of tau&#x2010;targeted immunotherapy: the path walked and the roads ahead. Frontiers in neuroscience 12: 798</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6224648</ArticleId><ArticleId IdType="pubmed">30450030</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak P, Schmidt R, Kontsekova E, Kovacech B, Smolek T, Katina S, Fialova L, Prcina M, Parrak V, Dal&#x2010;Bianco P et&#xa0;al (2018b) FUNDAMANT: an interventional 72&#x2010;week phase 1 follow&#x2010;up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease. Alzheimers Res Ther 10: 108</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6201586</ArticleId><ArticleId IdType="pubmed">30355322</ArticleId></ArticleIdList></Reference><Reference><Citation>Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S et&#xa0;al (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61: 46&#x2013;54</Citation><ArticleIdList><ArticleId IdType="pubmed">12847155</ArticleId></ArticleIdList></Reference><Reference><Citation>
R Core Team
(2018) R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing.
https://www.R-project.org/
</Citation></Reference><Reference><Citation>Rajamohamedsait H, Rasool S, Rajamohamedsait W, Lin Y, Sigurdsson EM (2017) Prophylactic active tau immunization leads to sustained reduction in both tau and amyloid&#x2010;&#x3b2; pathologies in 3xTg mice. Sci Rep 7: 17034</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719023</ArticleId><ArticleId IdType="pubmed">29213096</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Simon&#x2010;Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L et&#xa0;al (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21&#x2010;linked ALS&#x2010;FTD. Neuron 72: 257&#x2013;268</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Schelle J, Hasler LM, Gopfert JC, Joos TO, Vanderstichele H, Stoops E, Mandelkow EM, Neumann U, Shimshek DR, Staufenbiel M et&#xa0;al (2017) Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition. Alzheimers Dement 13: 701&#x2013;709</Citation><ArticleIdList><ArticleId IdType="pubmed">27750032</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson&#x2010;Wood K, Khan K et&#xa0;al (1999) Immunization with amyloid&#x2010;beta attenuates Alzheimer&#x2010;disease&#x2010;like pathology in the PDAPP mouse. Nature 400: 173&#x2013;177</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Schludi MH, May S, Grasser FA, Rentzsch K, Kremmer E, Kupper C, Klopstock T, German Consortium for Frontotemporal Lobar Degeneration , Bavarian Brain Banking Alliance , Arzberger T et&#xa0;al (2015) Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing. Acta Neuropathol 130: 537&#x2013;555</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4575390</ArticleId><ArticleId IdType="pubmed">26085200</ArticleId></ArticleIdList></Reference><Reference><Citation>Schludi MH, Becker L, Garrett L, Gendron TF, Zhou Q, Schreiber F, Popper B, Dimou L, Strom TM, Winkelmann J et&#xa0;al (2017) Spinal poly&#x2010;GA inclusions in a C9orf72 mouse model trigger motor deficits and inflammation without neuron loss. Acta Neuropathol 134: 241&#x2013;254</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5508040</ArticleId><ArticleId IdType="pubmed">28409281</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y et&#xa0;al (2016) The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. Nature 537: 50&#x2013;56</Citation><ArticleIdList><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu J, Fu H, Qiu G, Kaye P, Ilyas M (2013) Segmenting overlapping cell nuclei in digital histopathology images In 2013 35th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). pp 5445&#x2013;5448.</Citation><ArticleIdList><ArticleId IdType="pubmed">24110968</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, Phaneuf D, Dupre N, Petri S, Strong M, Kriz J, Julien JP (2011) Deregulation of TDP&#x2010;43 in amyotrophic lateral sclerosis triggers nuclear factor kappaB&#x2010;mediated pathogenic pathways. J Exp Med 208: 2429&#x2013;2447</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3256969</ArticleId><ArticleId IdType="pubmed">22084410</ArticleId></ArticleIdList></Reference><Reference><Citation>Truett GE, Heeger P, Mynatt RL, Truett AA, Walker JA, Warman ML (2000) Preparation of PCR&#x2010;quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). Biotechniques 29: 52, 54</Citation><ArticleIdList><ArticleId IdType="pubmed">10907076</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatsavayai SC, Yoon SJ, Gardner RC, Gendron TF, Vargas JN, Trujillo A, Pribadi M, Phillips JJ, Gaus SE, Hixson JD et&#xa0;al (2016) Timing and significance of pathological features in C9orf72 expansion&#x2010;associated frontotemporal dementia. Brain 139: 3202&#x2013;3216</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5790143</ArticleId><ArticleId IdType="pubmed">27797809</ArticleId></ArticleIdList></Reference><Reference><Citation>Westergard T, Jensen BK, Wen X, Cai J, Kropf E, Iacovitti L, Pasinelli P, Trotti D (2016) Cell&#x2010;to&#x2010;cell transmission of dipeptide repeat proteins linked to C9orf72&#x2010;ALS/FTD. Cell Rep 17: 645&#x2013;652</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5078984</ArticleId><ArticleId IdType="pubmed">27732842</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM (2013) Anti&#x2010;tau antibodies that block tau aggregate seeding in&#xa0;vitro markedly decrease pathology and improve cognition in&#xa0;vivo . Neuron 80: 402&#x2013;414</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3924573</ArticleId><ArticleId IdType="pubmed">24075978</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Wang LG, Han Y, He QY (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16: 284&#x2013;287</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C, Bien&#x2010;Ly N, Hersom M, Maloney JA, Meilandt WJ et&#xa0;al (2014) Therapeutic bispecific antibodies cross the blood&#x2010;brain barrier in nonhuman primates. Sci Transl Med 6: 261ra154</Citation><ArticleIdList><ArticleId IdType="pubmed">25378646</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Gendron TF, Grima JC, Sasaguri H, Jansen&#x2010;West K, Xu YF, Katzman RB, Gass J, Murray ME, Shinohara M et&#xa0;al (2016) C9ORF72&#xa0;poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat Neurosci 19: 668&#x2013;677</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5138863</ArticleId><ArticleId IdType="pubmed">26998601</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Bell S, Wang J, Wen S, Baloh RH, Appel SH (2015) TDP&#x2010;43 activates microglia through NF&#x2010;kappaB and NLRP3 inflammasome. Exp Neurol 273: 24&#x2013;35</Citation><ArticleIdList><ArticleId IdType="pubmed">26222336</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, Lehmer C, Michaelsen M, Mori K, Alterauge D, Baumjohann D, Schludi MH, Greiling J, Farny D, Flatley A et&#xa0;al (2017) Antibodies inhibit transmission and aggregation of C9orf72 poly&#x2010;GA dipeptide repeat proteins. EMBO Mol Med 9: 687&#x2013;702</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5412769</ArticleId><ArticleId IdType="pubmed">28351931</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>